Wednesday, December 11, 2013 Daily Archives

Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with MedImmune

Lonza and BioWa BioWa, Inc. and Lonza today announced that they have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune has licensed the companies’ POTELLIGENT® CHOK1SV Cell Line Technology for use in multiple proprietary antibodies in its pipeline. POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s industry leading GS Gene Expression System™. The…